Present updated data for RP2 in combination with Opdivo
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Updated data from this clinical trial, including initial data with RP2 in combination with Opdivo, is expected to be presented mid-year.”
What we found
Evidence strength A What the grades mean
The company presented updated data for the RP2 and Opdivo combination in June 2021, meeting the mid-year 2021 deadline.
-
A Replimune Group, Inc. 10-Q filed 2021-08-06
“In June 2021 we presented a data update from both the RP2 single agent and combination portions of this clinical trial” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Merger
- Indicative materiality
- Transformational rules
- Action
- Present
- Deliverable
- Updated RP2 combination data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-REPL-023102 · Corrections policy